<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111003</article-id><article-id pub-id-type="publisher-id">ACM-39680</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_77540854.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  细胞因子在胆管癌组织中的表达及与小肠细菌过度生长的关系探讨
  Study on the Relation between the Overexpression of Cytokines and Small Intestinal Bacterial Overgrowth in Cholangiocarcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>亚楠</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>晓莹</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>豪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>许</surname><given-names>琳</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属青岛市市立医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>16</fpage><lpage>23</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的 本研究通过检测胆管癌(CCA)患者小肠细菌过度生长(small intestinal bacterial overgrowth, SIBO)及胆管癌组织中细胞因子(IL-1β、IL-6和TNF-α)的表达水平，来探讨胆管癌患者中小肠细菌过度生长的发病率及其与炎症介质水平的关系。方法：在30例胆管癌患者及30例健康对照中使用葡萄糖氢呼气实验(glucose hydrogen breath test, GHBT)检测小肠细菌过度生长的发生情况；采用免疫组织化学技术(immunohistochemistry, IHC)检测胆管癌组织中IL-1β、IL-6和TNF-α的表达情况。结果：1) 胆管癌组SIBO阳性率为53.3%，健康对照组SIBO阳性率为16.7%，胆管癌组SIBO阳性率明显高于对照组(X
   <sup>2</sup> = 8.864, P &lt; 0.05)。2) 在胆管癌患者SIBO阳性组和阴性组间IL-1β、IL-6、TNF-α的表达水平有显著差异(P = 0.03, 0.024, 0.01)。结论：胆管癌患者较健康人群更容易发生SIBO，SIBO可能通过促进IL-1β、IL-6及TNF-α的表达影响胰腺癌的发生发展。
    Objective: In this work, we investigated the morbidity of small intestinal bacterial overgrowth (SIBO) and the expression of cytokines (IL-1β, IL-6 and TNF-α) level in CCA, to analyze the changes between SIBO and inflammatory medium level. Methods: 30 patients with CCA and 30 healthy controls were included in this study. Glucose hydrogen breath test (GHBT) was used to detect SIBO. The immunohistochemistry (IHC) was used to detect the expression of IL-1β, IL-6 and TNF-α in CCA tissues. Results: 1) The SIBO positive rate was 53.3% in 30 patients with CCA, and 16.7% in 30 healthy controls. The SIBO positive rate was significantly higher in the CCA group than in the control group (X
   <sup>2</sup> = 8.864, P &lt; 0.05). 2) The expression levels of IL-1β, IL-6, TNF-α were significantly different between the SIBO(+) group and the SIBO(−) group in patients with CCA (P = 0.03, 0.024, 0.01). Conclusions: Patients with CCA were more likely to develop SIBO than healthy people. SIBO may influence the development of CCA by promoting the expression of IL-1β, IL-6 and TNF-α. 
  
 
</p></abstract><kwd-group><kwd>胆管癌，小肠细菌过度生长，细胞因子, Cholangiocarcinoma</kwd><kwd> Small Intestinal Bacteria Overgrowth</kwd><kwd> Cytokines</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的 本研究通过检测胆管癌(CCA)患者小肠细菌过度生长(small intestinal bacterial overgrowth, SIBO)及胆管癌组织中细胞因子(IL-1β、IL-6和TNF-α)的表达水平，来探讨胆管癌患者中小肠细菌过度生长的发病率及其与炎症介质水平的关系。方法：在30例胆管癌患者及30例健康对照中使用葡萄糖氢呼气实验(glucose hydrogen breath test, GHBT)检测小肠细菌过度生长的发生情况；采用免疫组织化学技术(immunohistochemistry, IHC)检测胆管癌组织中IL-1β、IL-6和TNF-α的表达情况。结果：1) 胆管癌组SIBO阳性率为53.3%，健康对照组SIBO阳性率为16.7%，胆管癌组SIBO阳性率明显高于对照组(c<sup>2</sup> = 8.864, P &lt; 0.05)。2) 在胆管癌患者SIBO阳性组和阴性组间IL-1β、IL-6、TNF-α的表达水平有显著差异(P = 0.03, 0.024, 0.01)。结论：胆管癌患者较健康人群更容易发生SIBO，SIBO可能通过促进IL-1β、IL-6及TNF-α的表达影响胰腺癌的发生发展。</p></sec><sec id="s2"><title>关键词</title><p>胆管癌，小肠细菌过度生长，细胞因子</p></sec><sec id="s3"><title>Study on the Relation between the Overexpression of Cytokines and Small Intestinal Bacterial Overgrowth in Cholangiocarcinoma</title><p>Ya’nan Liu, Xiaoying Ma, Hao Xu, Lin Xu</p><p>Qingdao Municipal Hospital Affiliated to Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/3-1571827x4_hanspub.png" /></p><p>Received: Dec. 6<sup>th</sup>, 2020; accepted: Dec. 19<sup>th</sup>, 2020; published: Jan. 8<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/3-1571827x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: In this work, we investigated the morbidity of small intestinal bacterial overgrowth (SIBO) and the expression of cytokines (IL-1β, IL-6 and TNF-α) level in CCA, to analyze the changes between SIBO and inflammatory medium level. Methods: 30 patients with CCA and 30 healthy controls were included in this study. Glucose hydrogen breath test (GHBT) was used to detect SIBO. The immunohistochemistry (IHC) was used to detect the expression of IL-1β, IL-6 and TNF-α in CCA tissues. Results: 1) The SIBO positive rate was 53.3% in 30 patients with CCA, and 16.7% in 30 healthy controls. The SIBO positive rate was significantly higher in the CCA group than in the control group (c<sup>2</sup> = 8.864, P &lt; 0.05). 2) The expression levels of IL-1β, IL-6, TNF-α were significantly different between the SIBO(+) group and the SIBO(−) group in patients with CCA (P = 0.03, 0.024, 0.01). Conclusions: Patients with CCA were more likely to develop SIBO than healthy people. SIBO may influence the development of CCA by promoting the expression of IL-1β, IL-6 and TNF-α.</p><p>Keywords:Cholangiocarcinoma, Small Intestinal Bacteria Overgrowth, Cytokines</p><disp-formula id="hanspub.39680-formula8"><graphic xlink:href="//html.hanspub.org/file/3-1571827x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1571827x7_hanspub.png" /> <img src="//html.hanspub.org/file/3-1571827x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>胆管癌(cholangiocarcinoma, CCA)是最常见的胆道恶性肿瘤，也是第二常见的肝脏恶性肿瘤。由于胆管癌的细胞性质、解剖位置和早期不明显的临床特征，胆管癌的治疗方案有限，总生存率低。在一个大型队列研究中发现，胆管癌患者术后复发率高，对全身化疗治疗反应差，5年生存率不到5%。对胆管癌的理解不足，阻碍了对有效化疗和分子靶向治疗的探索。在健康宿主中，微生物存在于整个胃肠道，是肠道屏障功能、消化吸收和维持免疫稳态所必需的。近年来，细菌感染引起的炎症已被认为与多种消化道肿瘤相关。小肠细菌过度生长(small intestinal bacterial overgrowth, SIBO)是肠道微生物群失调的病理过程，研究显示小肠细菌过度生长可以通过多种机制破坏肠粘膜结构，干扰营养物质吸收，产生代谢物和毒素。另有研究显示炎症介质在消化道肿瘤微环境中发挥了重要的作用，其中起主要作用的细胞因子是肿瘤坏死因子-α (tumor necrosis factor-α, TNF-α)、白介素-1β (intelukin-1β, IL-1β)、白介素-6 (intelukin-6, IL-6)等。我们采用葡萄糖氢呼气试验(glucose hydrogen breath test, GHBT)检测胆管癌患者的小肠细菌过度生长，应用免疫组化(immunohistochemistry, IHC)实验方法检测胆管癌组织标本中IL-1、IL-6、TNF-α的表达情况，研究了小肠细菌过度生长与胆管癌炎症介质、细胞因子水平改变的关系。</p></sec><sec id="s6"><title>2. 资料</title><sec id="s6_1"><title>2.1. 研究对象</title><p>选择2019年1月至2020年1月在青岛大学附属青岛市市立医院肝胆外科确诊为胆管癌的住院患者30例(所行检查均提前告知患者，获得患者知情同意并签署知情同意书后进行)，并将其列为胆管癌组，这些患者均有术后病理支持。同时间段内随机选择健康查体的健康人群30例，将其列入对照组。胆管癌组，男性18例，女性12例，年龄44~79岁，平均年龄63.13 &#177; 9.62岁；对照组，男性19例，女性11例，年龄42~77岁，平均年龄60.50 &#177; 9.39岁；两组年龄及性别均无统计学差异(P = 0.288 &gt; 0.05)。</p><p>所有研究对象符合以下条件：1) 无炎症性肠病、功能性肠病、代谢性疾病等引起胃肠动力不良的疾病；2) 近4周内没有使用激素、抑酸药、抗生素和益生菌制剂；3) 没有长期大量吸烟、饮酒史；4) 近30天内没有进行消化道侵入性检查及治疗；5) 没有其他可以解释胃肠道症状的胃肠道和肠外疾病；6) 经患者及本院伦理委员会同意并签署相关知情同意书。</p></sec><sec id="s6_2"><title>2.2. 标本</title><p>术中取30例胆管癌的肿瘤组织2 g以上，先经过10%的甲醛液进行固定，再常规进行石蜡的包埋、切片，然后进行免疫组化染色。</p></sec><sec id="s6_3"><title>2.3. 实验仪器与设备</title><p>石蜡切片机(德国莱卡公司)；呼气氢测试仪(深圳市HHBT-01)；光学显微镜(日本Olympus公司)；HHBT-01型呼气氢测试仪(深圳市中核海得威生物科技有限公司)。</p></sec><sec id="s6_4"><title>2.4. 实验试剂</title><p>口服葡萄糖(批号：H51020441)：四川长威制药有限公司；IL-1β抗体、IL-6抗体、TNF-α抗体：北京博奥森生物技术有限公司；液体DAB酶底物显色试剂盒：北京博奥森生物技术有限公司。</p></sec></sec><sec id="s7"><title>3. 方法</title><sec id="s7_1"><title>3.1. 葡萄糖氢呼气试验(Glucose Hydrogen Breath Test, GHBT)</title><sec id="s7_1_1"><title>3.1.1. 检查前准备</title><p>1) 检查前至少1周停止促胃肠动力药物和泻药的使用。2) 检查前1天禁食可发酵的食物，如复杂的碳水化合物。3) 呼吸检测前禁食8~12小时。4) 检查当天禁止吸烟。5) 在呼吸测试期间保持安静，避免剧烈活动。</p></sec><sec id="s7_1_2"><title>3.1.2. 检测方法</title><p>首先检测空腹时呼气氢的基础值，然后在200 mL温开水中溶入葡萄糖(1.0 g/kg，最多60 g)，完全溶解后嘱受检者在5 min内将其全部喝完，在接下来的2 h内每隔20 min检测一次呼气氢浓度，共7次。</p></sec><sec id="s7_1_3"><title>3.1.3. SIBO诊断标准</title><p>基础呼气氢浓度 ≥ 20 ppm或摄入葡萄糖后呼气氢浓度较基线升高 ≥ 12 ppm时，认为存在小肠细菌过度生长(SIBO)，反之则为阴性 [<xref ref-type="bibr" rid="hanspub.39680-ref1">1</xref>]。</p></sec></sec><sec id="s7_2"><title>3.2. 免疫组化法检测IL-1β、IL-6、TNF-α的表达</title><p>采用SP法，操作按试剂盒说明书进行。结果判断参照Shimizu方法，在光学显微镜下对切片染色结果进行评估，选择10个高倍视野，根据染色程度和细胞着色分布范围进行半定量积分判定。切片标本基本不着色记0分，着色基本为浅黄色记1分，着色基本为棕黄色记2分，着色基本为棕褐色记3分；染色细胞所占百分率 &lt; 10%记为0分，10%~30%之间记为1分，30%~50%之间记为2分，比例在50%以上记为3分。上述两项得分之和作为最后评分标准，二者计分之和 ≤ 2分为阴性(−)，2~3分为弱阳性(+)，4~5分为中等阳性(++)，6~7分为强阳性(+++) [<xref ref-type="bibr" rid="hanspub.39680-ref2">2</xref>]。</p></sec><sec id="s7_3"><title>3.3. 统计方法</title><p>通过使用SPSS25．0统计软件进行统计学分析，计量资料采用均数 &#177; 标准差(x &#177; s)表示，计数资料采用X<sup>2</sup>检验，相关性分析采用X<sup>2</sup>检验，组间比较采用KS-检验和卡方检验，P &lt; 0.05认为差异有统计学意义。</p></sec></sec><sec id="s8"><title>4. 结果</title><sec id="s8_1"><title>4.1. 胆管癌组与健康对照组SIBO检测结果比较</title><p>分别对30例胆管癌患者和30例健康人群通过葡萄糖氢呼气试验进行SIBO的检测，根据时间、呼气氢浓度绘制曲线图，在20 min处呼气氢浓度快速上升，随时间的推移，呼气氢浓度逐渐下移(图1)。在30例胆管癌患者中，其中16例诊断为SIBO阳性(53.3%)，在30例健康对照组中，有5例诊断为SIBO阳性(16.7%)，胆管癌组SIBO阳性率明显高于对照组(P &lt; 0.05) (表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of SIBO positive rate in cholangiocarcinoma group and control grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >SIBO</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >阳性(例数)</td><td align="center" valign="middle" >阴性(例数)</td><td align="center" valign="middle" >合计</td><td align="center" valign="middle" >阳性率</td></tr><tr><td align="center" valign="middle" >胆管癌组</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >53.3%</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >16.7%</td></tr></tbody></table></table-wrap><p>表1. 胆管癌组和对照组SIBO阳性率的比较</p><p>χ<sup>2</sup> = 8.864，P &lt; 0.05。</p><p>图1. 时间–呼气氢浓度曲线图(灰色曲线为对照组，橙色曲线为胆管癌组，差异有统计学意义(P &lt; 0.05))</p></sec><sec id="s8_2"><title>4.2. 胆管癌患者癌组织中IL-1β、IL-6、TNF-α的表达</title><p>通过免疫组化的方法，对30例胆管癌标本的IL-1β、IL-6、TNF-α的表达水平进行检测。在胆管癌患者SIBO阳性组中，有12例患者癌组织中IL-1β为中–强阳性表达，有10例患者癌组织中IL-6为中–强阳性表达，有11例患者癌组织中TNF-α为中-强阳性表达，而在SIBO阴性组中，有5例患者癌组织中IL-1β为中–强阳性表达，有3例患者癌组织中IL-6为中–强阳性表达，有3例患者癌组织中TNF-α为中–强阳性表达，两组间IL-1β、IL-6、TNF-α表达水平有显著差异(P &lt; 0.05) (表2、图2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The expression of IL-1β, IL-6, TNF-α in 30 CCA tissue sample</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >IL-1β</th><th align="center" valign="middle"  colspan="2"  >IL-6</th><th align="center" valign="middle"  colspan="2"  >TNF-α</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >−~+</td><td align="center" valign="middle" >++~+++</td><td align="center" valign="middle" >−~+</td><td align="center" valign="middle" >++~+++</td><td align="center" valign="middle" >−~+</td><td align="center" valign="middle" >++~+++</td></tr><tr><td align="center" valign="middle" >SIBO阳性(16例)</td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >SIBO阴性(14例)</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle"  colspan="2"  >0.03</td><td align="center" valign="middle"  colspan="2"  >0.024</td><td align="center" valign="middle"  colspan="2"  >0.01</td></tr></tbody></table></table-wrap><p>表2. IL-1β、IL-6、TNF-α在30例胆管癌组织中的表达</p><p>图2. IL-1β (a)、IL-6 (b)、TNF-α (c)在胆管癌组织的免疫组化分析(&#215;100)</p></sec></sec><sec id="s9"><title>5. 讨论</title><p>胆管癌(CCA)是以胆管细胞分化为特征的肝胆恶性肿瘤，其发病率和死亡率在过去30年持续上升，只有极少数患者可以存活到诊断后的5年。肿瘤组织的侵袭可以促进炎症的发展，而炎症的发展同样也会增加某些癌症的发病率。继发于结石的慢性胆道炎 [<xref ref-type="bibr" rid="hanspub.39680-ref3">3</xref>] 以及小肠细菌过度生长 [<xref ref-type="bibr" rid="hanspub.39680-ref4">4</xref>] 已被提出可以增加胆道恶性肿瘤的患病风险。并且目前大量研究证实，细胞因子IL-1β、IL-6、TNF-α在消化道肿瘤的炎症反应中发挥了重要作用。在本研究中，我们观察到CCA患者SIBO阳性率为53.3%，并且SIBO阳性患者癌组织中IL-1β、IL-6、TNF-α的表达明显高于SIBO阴性患者。</p><p>在健康的宿主中，微生物存在于整个胃肠道，是维持肠道屏障功能、消化吸收和免疫稳态所必需的。小肠细菌过度生长(SIBO)是一种实体性疾病，它与小肠中大肠典型细菌数量的增加有关 [<xref ref-type="bibr" rid="hanspub.39680-ref5">5</xref>]。在生理状态下，多种因素限制了大肠细菌在小肠中的异常定植，如低胃酸pH、肠道的正常蠕动、肠粘膜和保护性粘液层的完整、回盲瓣的抗回流特性、共生菌群的保护作用以及局部和全身免疫。如果其中一种因素受到干扰，就有可能导致SIBO的发展。肠道微生物在小肠中的过度生长会损伤小肠绒毛，使消化酶的产生受损，肠道屏障功能障碍，导致吸收不良和营养物质的丢失。此外SIBO还会导致肠道通透性的改变，使细菌产物通过受损肠壁进入全身循环，引起全身炎症状态。一直以来，小肠液体抽吸液的培养及随后的细菌计数(&gt;105 CFU/ml)被认为是诊断SIBO的金标准 [<xref ref-type="bibr" rid="hanspub.39680-ref6">6</xref>]。然而，由于这种方法的侵袭性及高风险，目前普遍认为无创、操作方便、并且快速的葡萄糖氢呼气试验在临床实践中优于小肠细菌培养。来自2017年的北美共识同样建议采用呼气试验检测SIBO [<xref ref-type="bibr" rid="hanspub.39680-ref7">7</xref>]，这也是我们使用GHBT检测CCA患者SIBO患病率的重要依据。在过去的几十年里，许多研究在消化道肿瘤 [<xref ref-type="bibr" rid="hanspub.39680-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.39680-ref9">9</xref>]、慢性肝病和肝硬化患者中报告了肠道微生物组成的显著变化 [<xref ref-type="bibr" rid="hanspub.39680-ref10">10</xref>]。Quigley等人的研究发现SIBO与肝脏疾病的严重程度、病程及并发症的出现密切相关，特别是腹水、肝性脑病、自发性细菌性腹膜炎、门脉高压，以及伴随的失代偿性肝硬化 [<xref ref-type="bibr" rid="hanspub.39680-ref11">11</xref>]。Xiaoying Ma等人的研究表明SIBO在胰腺癌和胆管癌中的患病率明显高于健康对照，并且SIBO与TLR-4的表达呈正相关，提示SIBO可能是胰腺癌和胆管癌发病的危险因素，TLR-4信号通路可能参与其中 [<xref ref-type="bibr" rid="hanspub.39680-ref1">1</xref>]。我们的研究发现，SIBO阳性率在胆管癌组明显高于健康对照组，差异显著，表明胆管癌患者与健康人群相比更容易发生SIBO。早期诊断SIBO，并对肠道微生物紊乱进行调节，对于胆管癌患者的临床症状、生活质量以及远期预后有着重大意义。</p><p>胆管癌的发生与炎症反应密切相关，多种细胞因子、生长因子、酪氨酸激酶和胆汁酸已被证明与胆管癌发生相关的细胞增殖、凋亡、衰老和细胞周期的改变有关。既往研究已经发现炎症细胞因子可以通过激活诱生型一氧化氮合酶，使一氧化氮产能过量，进而导致单链、双链和氧化DNA损伤参与胆管癌的发展。</p><p>白细胞介素-1β (IL-1β)是由单核－巨噬细胞分泌的重要炎性因子，能活化多种细胞因子，产生炎症介质，促进白细胞聚集、浸润，放大炎症效应，触发机体免疫反应，增加机体的免疫应答能力。IL-1β的过表达会导致炎症和免疫之间的失衡进而促进肿瘤的发生、发展。许春蕾等人的研究发现炎性因子IL-1β能够促进胃癌细胞中细胞分裂周期蛋白42 (CDC42)的表达，过表达的CDC42可以通过调控NF-κB信号通路中的Slug、MMP-9蛋白来提高肿瘤细胞的增殖、迁移及浸润能力，从而促进胃癌的发生、发展 [<xref ref-type="bibr" rid="hanspub.39680-ref12">12</xref>]。陆兴热等人研究发现，胃腺癌患者血清中IL-1β水平显著升高，且胃癌患者癌组织中IL-1β的升高水平与患者的5年生存率、胃癌的浸润深度以及淋巴结转移均相关 [<xref ref-type="bibr" rid="hanspub.39680-ref13">13</xref>]。此外，Benjaporn Buranrat等人发现促炎细胞因子(IL-γ, IL-1β, TNF-α)可以通过抑制N-乙酰转移酶(NAT1)的解毒作用影响KKU-100胆管癌细胞的增殖、分化，并且这种作用与一氧化氮供体的处理效果类似 [<xref ref-type="bibr" rid="hanspub.39680-ref14">14</xref>]。</p><p>胆管癌细胞及基质炎性细胞可以以自分泌或旁分泌的方式产生IL-6，促进细胞存活，提供细胞有丝分裂信号。髓细胞白血病序列1 (MCL1)是抗凋亡BCL2家族中的一员，在胆管癌中调节肿瘤坏死因子相关的抗凋亡配体。IL-6通过信号转导，转录激活因子(STAT)通路和蛋白激酶B(Akt)的本构激活可以使MCL1的表达增加 [<xref ref-type="bibr" rid="hanspub.39680-ref15">15</xref>]。MCL1的转录则由IL-6通过p38丝裂原活化蛋白激酶(MAPK)依赖的信号通路激活。IL-6与gp130受体结合，导致随后的gp130相关JAK激酶(JAK激酶1和JAK激酶2)的二聚作用及活化，进一步导致STAT3的激活。持续的IL-6/STAT3信号通路进一步导致细胞因子信号传导抑制因子-3的表观遗传沉默 [<xref ref-type="bibr" rid="hanspub.39680-ref16">16</xref>]。这些研究都表明IL-6介导的炎症信号通路似乎可以通过引起DNA损伤和阻断DNA损伤反应诱导的凋亡来促进CCA的发展。Bei Lv等人在临床胆管癌标本中，发现IL-6水平与胆汁酸内源性受体–法尼酯X受体(FXR)的表达呈负相关。FXR通过抑制IL-6抑制胆管细胞的增殖、迁移、侵袭和上皮细胞间充质转换。FXR激动剂OCA在未来可能是治疗胆管癌的一种新药物 [<xref ref-type="bibr" rid="hanspub.39680-ref17">17</xref>]。Chiara Braconi等人还评估了IL-6在胆管癌生长调节和化疗反应中的作用 [<xref ref-type="bibr" rid="hanspub.39680-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.39680-ref19">19</xref>]，根据IL-6表达相关的表型变化，有助于在胆管癌的治疗中靶向选择更合适的治疗药物 [<xref ref-type="bibr" rid="hanspub.39680-ref20">20</xref>]。</p><p>TNF-α是由单核–巨噬细胞、肿瘤细胞产生的一种多肽细胞因子。在多种生理和免疫过程中可以刺激急性期反应，介导早期炎症反应，调节其他细胞因子、血细胞因子和内皮粘附分子的产生。TNF-α可以增加血管通透性，导致活化白细胞在感染或损伤部位的聚集，增强癌基因活化、肿瘤细胞侵袭和血管生成。肿瘤细胞TNF-α的表达可能是一种有效的免疫逃逸机制，通过诱导免疫细胞凋亡，导致肿瘤免疫反应的下调。最近关于TNF-α作用的实验和临床研究表明，TNF-α是人类结直肠癌(CRC)进展的关键因素 [<xref ref-type="bibr" rid="hanspub.39680-ref21">21</xref>]。Noyko Stanilov等人研究发现，结直肠癌患者血清TNF-α的水平明显高于对照组(P = 0.0000001)，在肿瘤淋巴结转移的亚组分析中，IV期TNF-α的血清水平与结直肠癌早期组和对照组相比明显升高。低TNF-α血清水平的CRC患者的生存率(中位生存期)与高TNF-α血清水平的患者相比明显延长 [<xref ref-type="bibr" rid="hanspub.39680-ref22">22</xref>]。这表明内源性TNF-α在CRC患者中起着负面作用，在CRC的生长和肿瘤的进展中更大可能是作为肿瘤促进因子在发挥作用，而不是抗肿瘤活性的细胞因子。</p><p>目前国内外关于小肠细菌过度生长与炎症介质的关系进行了一些研究。Srivastava D等人在印度的一项研究发现肠易激综合征(IBS)可能与小肠细菌过度生长(SIBO)引起的炎症反应有关。IBS患者血清IL-1α和IL-1β水平的升高与SIBO相关，并且粪便呈Bristol 6型的患者血清中IL-1β的水平明显高于粪便呈Bristol1-2型(P = 0.002)和Bristol3-5型(P = 0.007)的患者 [<xref ref-type="bibr" rid="hanspub.39680-ref23">23</xref>]。王锦辉等人在一项肝硬化患者的研究中发现，SIBO阳性患者的TNF-α、IL-6水平与SIBO阴性患者相比明显增高，提示SIBO与TNF-α及IL-6等细胞因子水平有关 [<xref ref-type="bibr" rid="hanspub.39680-ref24">24</xref>]。目前关于胆管癌患者SIBO与细胞因子的相关研究还较少。我们的研究发现SIBO阳性患者IL-1β、IL-6、TNF-α的表达明显高于阴性患者，提示小肠细菌过度生长在胆管癌的致病机制可能与菌群紊乱所致上述炎症因子过表达相关。</p></sec><sec id="s10"><title>6. 结论</title><p>综上所述，我们的研究表明在胆管癌中，SIBO和微生物区系失调的发病率很高，提示微生物区系失调可能是胆管癌发病的危险因素。通过免疫组化方法进一步发现SIBO阳性的胆管癌组织中IL-1β、IL-6、TNF-α的表达明显升高，表明SIBO在胆管癌的致病机制可能与IL-1β、IL-6、TNF-α的表达相关。我们的研究为胆管癌的防治和病因学探讨提供了新的见解，SIBO在胆管癌中的具体作用机制还需进一步研究。</p></sec><sec id="s11"><title>文章引用</title><p>刘亚楠,马晓莹,徐 豪,许 琳. 细胞因子在胆管癌组织中的表达及与小肠细菌过度生长的关系探讨Study on the Relation between the Overexpression of Cytokines and Small Intestinal Bacterial Overgrowth in Cholangiocarcinoma[J]. 临床医学进展, 2021, 11(01): 16-23. https://doi.org/10.12677/ACM.2021.111003</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39680-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ma, X., et al. (2019) Association between Small Intestinal Bacterial Overgrowth and Toll-Like Receptor 4 in Patients with Pancreatic Carcinoma and Cholangiocarcinoma. Turkish Journal of Gastroenterology, 30, 177-183.  
&lt;br&gt;https://doi.org/10.5152/tjg.2018.17512</mixed-citation></ref><ref id="hanspub.39680-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">朱明亭, 郑心. 间质流膏对肺纤维化大鼠TGF-β1、TNF-α、PDGF-BB与α-SMA表达干预的实验研究[D]: [硕士学位论文]. 济南: 山东中医药大学中医内科学, 2011.</mixed-citation></ref><ref id="hanspub.39680-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Tyson, G.L. and El-Serag, H.B. (2011) Risk Factors for Cholangiocarcinoma. Hepatology, 54, 173-184.  
&lt;br&gt;https://doi.org/10.1002/hep.24351</mixed-citation></ref><ref id="hanspub.39680-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">于兴华, 马晓莹, 许琳. 胆管癌化疗患者小肠细菌过度生长情况[J]. 中国微生态学杂志, 2019, 31(7): 803-807.</mixed-citation></ref><ref id="hanspub.39680-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Rezaie, A., Pimentel, M. and Rao, S. (2016) How to Test and Treat Small Intestinal Bacterial Overgrowth: An Evidence-Based Approach. Current Gastroenterology Reports, 18, 8. &lt;br&gt;https://doi.org/10.1007/s11894-015-0482-9</mixed-citation></ref><ref id="hanspub.39680-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Simrén, M. and Stotzer, P.O. (2006) Use and Abuse of Hydrogen Breath Tests. Gut, 55, 297-303.  
&lt;br&gt;https://doi.org/10.1136/gut.2005.075127</mixed-citation></ref><ref id="hanspub.39680-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Rezaie, A., Buresi, M., Lembo, A., et al. (2017) Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. The American Journal of Gastroenterology, 112, 775-784.  
&lt;br&gt;https://doi.org/10.1038/ajg.2017.46</mixed-citation></ref><ref id="hanspub.39680-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">王为, 刘峰, 徐爱蕾, 颜君, 蔡娜, 葛妍芹. 三种消化道恶性肿瘤小肠细菌过度生长情况的研究[J]. 医学综述, 2011, 17(6): 946-947.</mixed-citation></ref><ref id="hanspub.39680-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">刘扬, 李媛, 张东生, 张爱军, 许琳. 小肠细菌过度生长与小肠肿瘤的关系及其临床意义[J]. 世界华人消化杂志, 2013, 21(31): 3435-3439.</mixed-citation></ref><ref id="hanspub.39680-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Augustyn, M., Grys, I. and Kukla, M. (2019) Small Intestinal Bacterial Overgrowth and Nonalcoholic Fatty Liver Disease. Clinical and Experimental Hepatology, 5, 1-10. &lt;br&gt;https://doi.org/10.5114/ceh.2019.83151</mixed-citation></ref><ref id="hanspub.39680-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Quigley, E.M., Stanton, C. and Murphy, E.F. (2013) The Gut Microbiota and the Liver. Pathophysiological and Clinical Implications. Journal of Hepatology, 58, 1020-1027. &lt;br&gt;https://doi.org/10.1016/j.jhep.2012.11.023</mixed-citation></ref><ref id="hanspub.39680-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">许春蕾, 李娜, 汤旭山. IL-1β通过上调CDC42/NF-κB信号通路促进胃癌细胞的增殖、迁移及侵袭[J]. 现代免疫学, 2020, 40(6): 441-445+53.</mixed-citation></ref><ref id="hanspub.39680-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">陆兴热, 陈凤羽, 杨德兴. IL-1β基因多态性及幽门螺杆菌感染交互作用与胃癌发生的相关性研究[J]. 中华医院感染学杂志, 2015, 25(10): 2185-2187.</mixed-citation></ref><ref id="hanspub.39680-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Buranrat, B., Prawan, A., Sripa, B. and Kukongviriyapan, V. (2007) Inflammatory Cytokines Suppress Arylamine N-Acetyltransferase 1 in Cholangiocarcinoma Cells. World Journal of Gastroenterology, 13, 6219-6225.  
&lt;br&gt;https://doi.org/10.3748/wjg.v13.i46.6219</mixed-citation></ref><ref id="hanspub.39680-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Isomoto, H., Kobayashi, S., Werneburg, N.W., et al. (2005) Interleukin 6 Upregulates Myeloid Cell Leukemia-1 Expression through a STAT3 Pathway in Cholangiocarcinoma Cells. Hepatology, 42, 1329-1338.  
&lt;br&gt;https://doi.org/10.1002/hep.20966</mixed-citation></ref><ref id="hanspub.39680-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Isomoto, H., Mott, J.L., Kobayashi, S., et al. (2007) Sustained IL-6/STAT-3 Signaling in Cholangiocarcinoma Cells Due to SOCS-3 Epigenetic Silencing. Gastroenterology, 132, 384-396. &lt;br&gt;https://doi.org/10.1053/j.gastro.2006.10.037</mixed-citation></ref><ref id="hanspub.39680-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Lv, B., Ma, L., Tang, W., et al. (2018) FXR Acts as a Metastasis Suppressor in Intrahepatic Cholangiocarcinoma by Inhibiting IL-6-Induced Epithelial-Mesenchymal Transition. Cellular Physiology and Biochemistry, 48, 158-172.  
&lt;br&gt;https://doi.org/10.1159/000491715</mixed-citation></ref><ref id="hanspub.39680-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Wehbe, H., Henson, R., Meng, F., Mize-Berge, J. and Patel, T. (2006) Interleukin-6 Contributes to Growth in Cholangiocarcinoma Cells by Aberrant Promoter Methylation and Gene Expression. Cancer Research, 66, 10517-10524.  
&lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-06-2130</mixed-citation></ref><ref id="hanspub.39680-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Meng, F., Yamagiwa, Y., Ueno, Y. and Patel, T. (2006) Over-Expression of Interleukin-6 Enhances Cell Survival and Transformed Cell Growth in Human Malignant Cholangiocytes. Journal of Hepatology, 44, 1055-1065.  
&lt;br&gt;https://doi.org/10.1016/j.jhep.2005.10.030</mixed-citation></ref><ref id="hanspub.39680-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Braconi, C., Swenson, E., Kogure, T., Huang, N. and Patel, T. (2010) Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma. PLoS ONE, 5, e15195.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0015195</mixed-citation></ref><ref id="hanspub.39680-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Loris, B. and Simone, M. (2010) The Dual Role of Tumor Necrosis Factor (TNF) in Cancer Biology. Current Medicinal Chemistry, 17, 3337-3352. &lt;br&gt;https://doi.org/10.2174/092986710793176339</mixed-citation></ref><ref id="hanspub.39680-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Stanilov, N., Miteva, L., Dobreva, Z. and Stanilova, S. (2014) Colorectal Cancer Severity and Survival in Correlation with Tumour Necrosis Factor-Alpha. Biotechnology &amp; Biotechnological Equipment, 28, 911-917.  
&lt;br&gt;https://doi.org/10.1080/13102818.2014.965047</mixed-citation></ref><ref id="hanspub.39680-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Srivastava, D., Ghoshal, U., Mittal, R.D. and Ghoshal, U.C. (2014) Associations between IL-1RA Polymorphisms and Small Intestinal Bacterial Overgrowth among Patients with Irritable Bowel Syndrome from India. Neurogastroenterology &amp; Motility, 26, 1408-1416. &lt;br&gt;https://doi.org/10.1111/nmo.12399</mixed-citation></ref><ref id="hanspub.39680-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">王锦辉, 陈旻湖, 何瑶. 肝硬化患者小肠细菌过度生长与内毒素血症[J]. 中华内科杂志, 2002, 41(7): 30-32.</mixed-citation></ref></ref-list></back></article>